Shots:

• The company has completed the enrollment in the P-III C.L.E.A.R. program evaluating SP-102 vs PBO in 400 patients with lumbosacral radicular pain or sciatica at 40 sites across 25 states in the US. The results are expected in Q4’21
• The 1EPs of the study is mean change in the numeric pain rating scale for leg pain @ 4 wks. Additionally- a trial is designed to assess 2EPs including other measures of pain i.e.- back pain- time to repeat injection of SP-102- safety & function @ 4 & 12 wks.
• If approved by the FDA- SP-102 would be the 1st non-opioid epidural injection for sciatica & will be available in a pre-filled syringe. The therapy also received FT designation from the FDA

  | Ref: Globe Newswire | Image: Scilex Holding